Canada will be the first commercial market to launch i-FACTOR®+ Matrix
Find out moreThe IDE Supplement allows for a reduction in the total number of patients required to be enrolled in the ASPIRE IDE Study on P15-L bone graft in the lumbar spine.
Find out moreData published in The Spine Journal show elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rate with i-FACTOR bone graft compared to allograft
Find out morei-FACTOR® Peptide Enhanced Bone Graft continues to demonstrate statistical superiority to autologous bone in cervical spine surgery
Find out more